Literature DB >> 27282652

Neuro-oncology: Amino acid PET for brain tumours - ready for the clinic?

Karl-Josef Langen1, Colin Watts2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27282652     DOI： 10.1038/nrneurol.2016.80

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.

Authors:  Norbert Galldiks; Gabriele Stoffels; Christian Filss; Marion Rapp; Tobias Blau; Caroline Tscherpel; Garry Ceccon; Veronika Dunkl; Martin Weinzierl; Michael Stoffel; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

Review 3.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

4.  Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460].

Authors:  Karl-Josef Langen; Jörg C Tonn; Michael Weller; Norbert Galldiks
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

5.  Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.

Authors:  Alexander Heinzel; Stephanie Stock; Karl-Josef Langen; Dirk Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-15       Impact factor: 9.236

Review 6.  11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.

Authors:  Tarun Singhal; Tanjore K Narayanan; Viney Jain; Jogeshwar Mukherjee; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2007-10-24       Impact factor: 3.488

7.  MR imaging in cerebral gliomas. Tissue component analysis in correlation with histopathology of whole-brain specimens.

Authors:  M Tovi; M Hartman; A Lilja; A Ericsson
Journal:  Acta Radiol       Date:  1994-09       Impact factor: 1.990

Review 8.  Clinical value of O-(2-[(18)F]-fluoroethyl)-L-tyrosine positron emission tomography in patients with low-grade glioma.

Authors:  Marion Rapp; Frank W Floeth; Jörg Felsberg; Hans-Jakob Steiger; Michael Sabel; Karl-Josef Langen; Norbert Galldiks
Journal:  Neurosurg Focus       Date:  2013-02       Impact factor: 4.047

Review 9.  The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy Charles Ryken; Nafi Aygun; Johnathan Morris; Marin Schweizer; Rajeshwari Nair; Cassandra Spracklen; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-09       Impact factor: 4.130
  9 in total
  27 in total

1.  Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury.

Authors:  Francesco Cicone; Norbert Galldiks; Giuseppe Minniti; Christian P Filss; Francesco Scopinaro; John O Prior; Nathalie L Albert; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

2.  Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-L-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake.

Authors:  Carina Stegmayr; Gabriele Stoffels; Elena Rota Kops; Philipp Lohmann; Norbert Galldiks; Nadim J Shah; Bernd Neumaier; Karl-Josef Langen
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

Review 3.  Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.

Authors:  Alipi V Bonm; Reed Ritterbusch; Patrick Throckmorton; Jerome J Graber
Journal:  J Neuroimaging       Date:  2020-01-10       Impact factor: 2.486

4.  Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.

Authors:  Norbert Galldiks; Marcus Unterrainer; Natalie Judov; Gabriele Stoffels; Marion Rapp; Philipp Lohmann; Franziska Vettermann; Veronika Dunkl; Bogdana Suchorska; Jörg C Tonn; Friedrich-Wilhem Kreth; Gereon R Fink; Peter Bartenstein; Karl-Josef Langen; Nathalie L Albert
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

5.  PET imaging in patients with brain metastasis-report of the RANO/PET group.

Authors:  Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2019-05-06       Impact factor: 12.300

6.  Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.

Authors:  Garry Ceccon; Lazaros Lazaridis; Gabriele Stoffels; Marion Rapp; Manuel Weber; Tobias Blau; Phillip Lohmann; Sied Kebir; Ken Herrmann; Gereon R Fink; Karl-Josef Langen; Martin Glas; Norbert Galldiks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-21       Impact factor: 9.236

7.  Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Authors:  Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

8.  MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study.

Authors:  Shuangshuang Song; Yi Shan; Leiming Wang; Ye Cheng; Hongwei Yang; Guoguang Zhao; Zhenguang Wang; Jie Lu
Journal:  Eur Radiol       Date:  2022-02-22       Impact factor: 7.034

9.  Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status.

Authors:  Shuangshuang Song; Leiming Wang; Hongwei Yang; Yongzhi Shan; Ye Cheng; Lixin Xu; Chengyan Dong; Guoguang Zhao; Jie Lu
Journal:  Eur Radiol       Date:  2020-11-19       Impact factor: 5.315

10.  Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment?

Authors:  Marcus Unterrainer; Franziska Vettermann; Matthias Brendel; Adrien Holzgreve; Michael Lifschitz; Matthias Zähringer; Bogdana Suchorska; Vera Wenter; Ben M Illigens; Peter Bartenstein; Nathalie L Albert
Journal:  EJNMMI Res       Date:  2017-05-30       Impact factor: 3.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.